Trials / Conditions / Recurrent Oropharyngeal Squamous Cell Carcinoma

Recurrent Oropharyngeal Squamous Cell Carcinoma

26 registered clinical trials studyying Recurrent Oropharyngeal Squamous Cell Carcinoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038	National Cancer Institute (NCI)	Phase 2
Not Yet Recruiting	Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ NCT07156227	National Cancer Institute (NCI)	Phase 1
Recruiting	TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Nec NCT06868433	Emory University	Phase 1
Recruiting	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returni NCT06589804	National Cancer Institute (NCI)	Phase 3
Recruiting	Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058	Emory University	N/A
Recruiting	Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, NCT06636734	Emory University	Phase 2
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) NCT05172258	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcin NCT04862650	Marcelo Bonomi	Phase 2
Recruiting	Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treat NCT04671667	National Cancer Institute (NCI)	Phase 2
Terminated	NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery NCT04588038	Hyunseok Kang, MD	Phase 1
Recruiting	Oropharynx (OPX) Biomarker Trial NCT06356272	Mayo Clinic	—
Active Not Recruiting	Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer NCT03468218	Emory University	Phase 2
Terminated	BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer NCT02706691	University of Chicago	Phase 2
Completed	Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell NCT03422536	University of Arizona	Phase 2
Terminated	Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer NCT02388932	Case Comprehensive Cancer Center	N/A
Terminated	Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer NCT02068157	Roswell Park Cancer Institute	Phase 2
Terminated	Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Ne NCT02196168	National Cancer Institute (NCI)	Phase 2
Completed	Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer NCT01254617	National Cancer Institute (NCI)	Phase 1
Terminated	Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT01267240	National Cancer Institute (NCI)	Phase 2
Completed	Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who D NCT01256385	National Cancer Institute (NCI)	Phase 2
Completed	Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recur NCT01064479	M.D. Anderson Cancer Center	Phase 2
Completed	Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer NCT02007200	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squam NCT00588770	National Cancer Institute (NCI)	Phase 3
Active Not Recruiting	Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent NCT00494182	M.D. Anderson Cancer Center	Phase 2
Completed	Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer NCT00458978	National Cancer Institute (NCI)	Phase 2